66 results about "Increase muscle mass" patented technology

The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.

The present invention relates to the field of biotechnology and discloses a probiotic composition for alleviating sarcopenic obesity and its use. The composition comprises at least two of Lactobacillus plantarum, Lactobacillus rhamnosus, and Bifidobacterium animalis subsp. lactis; wherein the Lactobacillus plantarum has a deposit number of CGMCC No. 25839; the Lactobacillus rhamnosus has a deposit number of CGMCC No. 26968; and the Bifidobacterium animalis subsp. lactis has a deposit number of CGMCC No. 27998. The composition of the present invention can increase muscle mass, improve muscle tissue morphology, increase adenosine triphosphate, and inhibit abnormal weight gain, thereby effectively preventing and treating sarcopenic obesity.

Disclosed herein are the Lactobacillus paracasei NB23 strain and a method of using the same to increase muscle mass and to prevent / treat metabolic syndrome. Administering an effective amount of the Lactobacillus paracasei NB23 strain or a metabolite thereof to an individual can effectively produce the effect of treating or preventing diseases associated with muscle loss or insufficient muscle mass, metabolic syndrome, and diseases related thereto.

The present disclosure relates to microbiome compositions for improving muscle strength using a heat-treated fermentative culture complex of KM2 Phytobacterium plantarum. The composition according to the present disclosure increases the synthesis of myoprotein and exhibits an effect of inhibiting the degradation of myoprotein. Animal tests show effects of improving muscle strength and increasing leg muscle mass by increasing grip strength, travel distance and speed, and results of improving popliteal muscle strength and increasing muscle mass even in clinical tests. Furthermore, it has been found that beneficial bacteria are increased by an increase in the diversity of the gut microbial flora, which varies as muscle decreases, and an improvement in the microbial flora composition, while harmful bacteria are reduced. Therefore, the composition can be used as a composition for preventing, alleviating or treating muscle diseases and a composition for improving muscle strength or increasing muscle mass.

Provided are compositions comprising, and methods of administering, gene therapy vectors, particularly recombinant AAV vectors encoding AUF1 proteins for expression in muscle cells for restoring or increasing muscle mass, muscle function or performance, and / or reducing or reversing muscle atrophy. The compositions and methods may be used for the treatment of subject suffering from sarcopenia, muscle degenerative disease or traumatic injury.

Provided is a humanized antibody that, through IGF-I receptor, increases muscle mass but does not lower the blood glucose level. This humanized antibody: is an anti-IGF-I receptor humanized antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 serving as a CDR sequence; and specifically binds to IGF-I receptor extracellular domain.

The present disclosure relates to a composition for preventing or treating muscle disease, comprising CXCL14 as an active ingredient. According to the present disclosure, it was confirmed that CXCL14 increased muscle differentiation and synthesis, thereby increasing muscle mass. In addition, it was confirmed that in LPS-induced muscular atrophy or DEX-induced muscular dystrophy, CXCL14 inhibited muscle loss, increased the expression of muscle synthesis and differentiation factors, and inhibited the expression of muscle degradation proteins. In addition, it was confirmed that CXCL14 promoted muscle synthesis and differentiation and inhibited the muscle degradation even in vivo.

This invention relates to the field of biotechnology, and more particularly to a swelling-promoting seahorse oil and its application in the preparation of anti-sarcopenia products. Obtained using a supercritical carbon dioxide extraction process, the swelling-promoting seahorse oil of this invention has been experimentally verified to inhibit muscle degradation, promote muscle cell activation and differentiation, increase muscle mass, and enhance muscle strength and endurance. Furthermore, it exerts its effects through dietary supplementation with no significant adverse reactions, and can be used to prepare anti-sarcopenia related foods, health products, or pharmaceuticals to meet the muscle health maintenance needs of the elderly.

The present invention relates to a composition for the improvement and treatment of muscle diseases and cachexia, wherein diflunisal has the effect of promoting the differentiation and proliferation of myogenic cells, and further has the effect of improving and treating cachexia induced by chronic diseases such as muscle diseases or cancer through effects such as increased muscle mass and recovery of muscle strength.

It was confirmed that probiotic metabolites of the present invention protect muscle cells and promote differentiation of muscle fibers. In addition, it was confirmed in an animal model of muscle atrophy or sarcopenia induced by dexamethasone that probiotic metabolites increased muscle mass and muscle function, inhibited expression of factors associated with muscle degradation, and increased expression of factors associated with muscle synthesis and regeneration. It was confirmed that probiotic metabolites contribute to alleviation of muscle atrophy by regulating sugar, amino acid, and fatty acid metabolism altered by dexamethasone.

The present invention relates to a composition, as well as a tablet, capsule or juice for oral administration, and its use as an anti-aging agent. The present invention also relates to the use of a composition, tablet, capsule or juice, for providing a balanced protein supply, and / or for improving the utilization of amino acids in a cell and / or in an organism. In addition, the present invention also relates to the use of a composition, a tablet, a capsule or a juice, for increasing the build-up of muscle mass, for stimulating metabolic performance, for positively influencing inflammatory processes, and / or for positively influencing the aging process of a cell and / or an organism. The present invention also relates to a composition, a tablet, a capsule or a juice, for use as a medicament. Furthermore, the present invention also relates to a composition, tablet, capsule or juice, for use in a method for the prevention or treatment of age-related disorders and / or diseases.

The present invention provides a composition and method for increasing muscle mass, preventing muscle atrophy, and promoting muscle growth. [Solution] In certain aspects, the disclosed composition comprises dileucine and leucine and pharmaceutically acceptable salts thereof. In certain aspects, the disclosed composition is administered to subjects in need to increase muscle mass, prevent muscle atrophy, and / or promote muscle growth.

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and / or agents which lead to increased muscle mass.

The present invention is focused on extending the lifespan and the healthy period of life (healthspan), delaying the development of chronic diseases and dysfunctions, which is a growing need of aging societies. Among the strategies to promote and extend healthspan, nutrition and food ingredients play a central role. The present invention is related to standardized delphinidin-rich maqui berry composition comprising different amounts and combination of delphinidins, which represent a potent class of antioxidant anthocyanins as agent for reducing progressive loss of skeletal muscle, increasing muscle mass and anti-aging agent or geroprotective agent, and thereby, enhancing the healthspan and preserving locomotive functions for longer periods of life. Such effect was measured as climbing ability during life time in an animal model (Drosophila melanogaster), Experimental assays demonstrated that delphinidin-rich standardized maqui berry extracts upregulate the expression of antioxidant enzymes and mitochondrial homeostasis-related proteins, which determine contractile muscle function. Such delphinidin-rich standardized maqui berry composition is useful as antioxidant supplement for adults and elderly.

The apelin receptor modulator can improve the physical performance of a human patient, slow the progression of age-related weakness, and can reduce age-related muscle weakness. The present disclosure provides methods of treating muscle disorders using specific classes of apelin receptor modulators (e.g., agonists). The muscle condition may be an age-related muscle condition. Also provided is a method of maintaining and / or increasing muscle mass, muscle function, and / or muscle strength in an elderly subject by administering an apelin receptor modulator. In some embodiments, an apelin receptor modulator (e.g., an agonist) is BGE-105 or a pharmaceutically acceptable salt thereof.

The present invention concerns a method for preventing muscle injuries and / or fatigue in a subject comprising the step of simultaneously, separately, or sequentially administrating to a subject in need thereof an effective amount of i) at least 20-Hydroxyecdysone, ii) at least rosavin, iii) at least one Medium-chain triglycerides (MCTs) and unsaturated fatty acid enriched oil, and iv) optionally a pharmaceutically acceptable carrier.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

The present invention relates to a composition comprising an Alox5 inhibitor for preventing or treating sarcopenia, and comprises a material that targets Alox5 so as to inhibit the expression or activation thereof, and thus improves muscular performance, increases muscle mass and cross-sectional areas of muscle fibers, and reduces the expression of myoatrophy regulators, thereby effectively preventing, alleviating and treating sarcopenia.

The present invention relates to uses of cyclo(his-pro) (CHP) for enhancing exercise performance, improving muscle function, or preventing, alleviating, or treating muscle diseases and, more specifically, provides a pharmaceutical composition, a food composition, a feed additive, a method for enhancing exercise performance, a method for improving muscle function or for preventing, alleviating, or treating muscle diseases, and a method for enhancing muscle strength, each using cyclo(his-pro) as an active ingredient, wherein the cyclo(his-pro) can be used not only in enhancing exercise performance and strengthening muscle strength by exhibiting effects of increasing muscle strength, movement coordination, resistance to muscle fatigue, sense of balance, and muscle energy production, but also in enhancing muscle function or preventing, alleviating, or treating muscle diseases by exhibiting effects of increasing muscle mass and muscle fiber size, inhibiting muscle loss, muscle atrophy, and improving muscle energy production.

Compositions including an amino acid component including: L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-threonine, L-tryptophan, L-valine and L-arginine and optimized levels of L-methionine. L-tryptophan content may also be elevated and optimized, and additional amino acids including arginine, L-arginine, L-citrulline, L-carnitine and L-cysteine may optionally be present. Methods of treating muscle, wounds, surgical procedures, skin conditions and other conditions using such compositions are also provided.

The present invention relates to the use of a hemp seed extract for preventing or ameliorating muscle diseases by promoting myoblast differentiation or muscle regeneration. In the present invention, the hemp seed extract may exhibit preventive or therapeutic effects on various muscle diseases by increasing muscle mass, strengthening muscle power, improving muscle function, and enhancing exercise performance, and also has an effect of improving muscle function in healthy individuals in addition to treating muscle diseases.

This application relates to animals or cells possessing a myostatin gene, wherein 12 base pairs of the second exon of the myostatin gene are deleted. This application may also include compositions capable of manipulating the deletion of 12 base pairs of the myostatin gene to construct animals or cells. This application also relates to the use of this composition for increasing muscle mass.

The present invention relates to a composition comprising an Alox5 inhibitor for preventing or treating sarcopenia, and comprises a material that targets Alox5 so as to inhibit the expression or activation thereof, and thus improves muscular performance, increases muscle mass and cross-sectional areas of muscle fibers, and reduces the expression of myoatrophy regulators, thereby effectively preventing, alleviating and treating sarcopenia.

A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and / or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and / or a variant thereof and / or fragments thereof.

The present invention relates to a peptide having the activities of inhibiting sarcopenia, promoting muscle growth, and inhibiting fatty liver. The peptide according to the present invention can promote the proliferation of muscle cells and the differentiation thereof into muscle fibers, has a muscle regeneration effect even under conditions of muscular atrophy, and can significantly inhibit the expression of fat synthesis-related genes / proteins in hepatocytes. Thus, the peptide according to the present invention is expected to be effectively used for inhibiting sarcopenia, promoting muscle growth, and inhibiting fatty liver.

The present invention relates to a composition for increasing muscle mass, improving muscle function, or preventing or treating muscle disease, comprising Phocaeicola vulgatus or cultures thereof. In addition, the present invention relates to a method for increasing muscle mass, improving muscle function,, or preventing or treating muscular disease, comprising administering or taking a composition comprising Phocaeicola vulgatus or a culture thereof as an active ingredient to an individual in need. The Phocaeicola vulgatus of the present invention has the outstanding effect of increasing muscle strength, increasing muscle weight, and increasing muscle fiber.

The present invention provides a polypeptide consisting of the sequence of SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and / or treatment of a muscle disease or disorder. The present invention also provides a nucleic acid sequence encoding the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the present invention may be administered in the form of a pharmaceutical composition, together with at least one pharmaceutically acceptable excipient, diluent, or carrier. The present invention also provides non-therapeutic methods for improving muscle function and / or increasing muscle mass in a subject.

The present technology comprises methods of treating, preventing, reducing, or otherwise ameliorating one or more symptoms or conditions that may benefit from weight gain or a reduction in weight loss. The methods comprise administering a non-naturally occurring melanocortin analog of the present technology to a subject in need thereof. The methods may promote fat gain (e.g., epididymal fat or perirenal fat), increase muscle mass, increase body weight, accelerate weight gain, increase fat mass to lean mass ratio, improve body composition and / or BMI (e.g., for underweight conditions), increase waist circumference, increase cardiac mass, increase brain mass, or any combination thereof, relative to a control.

The invention provides novel antibodies that bind to activin type IIB receptor (ActRITB), or activin type IIA receptor (ActRIIa) or both. The antibodies block ligand binding to the receptors and modulate downstream signaling. The invention also provides novel compositions and methods for treating a metabolic disorder, improving glycemic control, promoting increased muscle mass, and reducing adipose tissue and treating osteoarthritis. The methods and compositions are used to treat type 2 diabetes.

Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.